recent non-random transmiss brca1 mutant allel off-spring carrier suggest confirm studi find will import implic both risk assess understand brca1 biologi howev kind analysi easi perform due sever ascertain bias inher identif brca1 carrier report propos differ approach overcom bias present addit data support non-random transmiss brca1 mutant allel
protect efficaci xenogen vaccin dna encod her2 oncogen evalu balb/c mice transgen transform form neu oncogen spontan develop carcinoma mammari gland intramuscular inject plasmid dna follow electr stimul pvij-her2 adenovir vector ad5-her2 both express her2 oncogen test immun us pvij-her2 elicit cell-mediat respons much lower elicit immun ad5-her2 measur frequenc ifn-gamma-secret spleen cell domin t-cell epitop her2 protein product p185 balb/c h-2 genet background identifi t-cell respons elicit partial crossreact correspond rat epitop becaus sequenc variat similar cytotox t-lymphocyt activ rat immunodomin epitop evid ad5-her2 vaccin induc antibodi p185 crossreact rat protein homolog both b-cell respons slowli declin time vaccin ad5-her2 week ag delai incid reduc multipl tumor neu transgen mice
epidemiolog studi indic ataxia-telangiectasia heterozygot famili increas risk cancer particularli breast cancer howev case-control studi signific differ found frequenc atm mutat patient control studi missens mutat found frequent truncat mutat suggest cancer risk depend mutat type investig possibl assess risk accord type posit atm truncat mutat extend famili dna rna isol blood buccal cell children rel screen atm germ-line mutat us restrict endonucleas fingerprint protein truncat test fluoresc-assist mismatch analysi direct sequenc standard incid ratio cancer associ atm heterozygos statu type mutat estim test genotyp-phenotyp correl simul permut mutat among parent branch signific differ found rel risk breast cancer type cancer base mutat type howev occurr associ truncat mutat certain bind domain atm protein e.g p53/brca1 beta-adaptin fat domain 0.006 limit sampl set presenc missens truncat atm mutat associ differ cancer risk risk appear associ alter bind domain rather length predict atm protein
need toxic adjuv therapi better understand process immun system erad micrometastat diseas gener signific interest breast cancer immunotherapi potenti approach stimul immun respons tumor rel advantag disadvantag regard cost immunogen clinic applic treat breast cancer articl will review mechan immun system recogn erad neoplast cell variou method stimul anti-tumor immun respons obstacl clinic effect immunotherapi breast cancer discuss
potenti therapi overwhelm on consid 000 patient candid annual unit state ideal therapi safe painless possibl access effect reduc local recurr becaus novelti techniqu therapi met goal ideal attain question remain follow patient regard frequenc imag modal local recurr technolog refin matur conceiv futur treatment breast cancer morbid open breast biopsi us just diagnosi diseas
ductal lavag minim-invas procedur permit sampl breast ductal fluid cytopatholog analysi techniqu perform topic anesthesia involv cannul fluid-yield nippl orific special-design cathet lavag aspir ductal system procedur us women clinic evid increas breast cancer risk atypia detect strengthen woman's interest commit risk-reduc strategi chemoprevent trial technolog us tool ongo translat research studi
articl briefli review excit yet unproven report altern method predict outcom breast cancer highlight molecular method diagnos classifi treat diseas author start review well-known factor breast cancer altern method stage predict outcom compar prospect
articl present author's current approach manag breast cancer older women emphasi clinic surgic treatment diseas popul controversi surround manag breast cancer popul regard adjuv therapi radiat therapi surgic option endeavor address issu articl
earli-stage breast cancer highli curabl diseas well-establish protocol includ surgeri adjuv modal region radiat therapi chemotherapi hormon therapi yet clear evid adjuv modal underus significantli articl review evid support us efficaci local system therapi earli-stage breast cancer reason underus intervent proven effect ensur deliveri appropri breast cancer care suggest strategi improv qualiti breast cancer care
breast cancer treatment underserv popul continu deviat establish guidelin signific barrier persist system physician patient level ultim affect surviv advers success strategi reduc dispar develop improv outcom popul women
evid high circul level insulin-like growth factor-i igf-i associ increas risk breast cancer among premenopaus women lend credenc hypothesi genet polymorph igf-i gene involv diseas popul-base case-control studi conduct assess associ igf-i gene polymorph repeat promot region] breast cancer risk plasma igf-i level chines women studi includ 041 incid breast cancer case diagnos august 1996 through march 1998 shanghai 086 randomli select ag frequenc-match control gener popul relat plasma igf-i level igf-i genotyp found women carri genotyp contain allel associ significantli decreas 0.80 0.64-1.00 increas 1.23 1.04-1.47 risk breast cancer respect women carri genotyp contain rare allel associ nonsignificantli increas risk breast cancer 1.92 0.92-4.02 compar carri specif allel associ allel predominantli present among premenopaus women dose-respons manner meta-analysi result indic igf-i genotyp contain consist associ increas risk breast cancer across studi overal 1.22 1.06-1.41 heterogen test 0.524 find studi support hypothesi igf-i gene polymorph signific genet factor breast cancer suscept
breast cancer incid sweden approxim twice high singapor recent year differ limit postmenopaus women aim studi explor reason behind differ through us ag-period-cohort model popul-base studi includ breast cancer case report swedish singapor cancer registri 1968 1997 total 135 581 swedish 716 singaporean women poisson regress us ag-period ag-cohort model us determin effect ag diagnosi calendar period birth cohort incid rate ratio us summar effect ag-cohort model provid best fit data both countri indic chang lifetim rather recent differ medic surveil account observ differ popul chang birth cohort much greater among singaporean women rel effect ag similar countri analys show ag cohort effect explain differ trend femal breast cancer incid sweden singapor larger cohort effect singaporean women attribut rapid chang reproduct lifestyl pattern swedish women period studi incid breast cancer postmenopaus women singapor will probabl continu rise come decad match current swedish rate
interact insulin-like growth factor receptor igf-ir ligand report induc cell prolifer transform blockad cell apoptot function igf-ir overexpress numer tumor cell type blockad import anti-cancer therapi gener human anti-igf-ir antibodi h7c10 block vitro igf-i igf-ii-induc cell prolifer mcf-7 breast cancer cell analysi igf-i transduct cascad demonstr human anti-igf-ir antibodi murin parent form block igf-i-induc tyrosin phosphoryl both beta-chain ir-1 tyrosin phosphoryl presum lead cell cycl arrest consequ growth inhibit treatment nude mice bear human breast cancer cell mcf-7 non small lung cancer cell a549 h7c10 murin parent form 7c10 inhibit significantli tumor growth almost complet inhibit a549 tumor growth observ mice treat anti-igf-ir antibodi combin chemotherapeut agent vinorelbin anti-epiderm growth factor receptor egfr antibodi 225 combin therapi prolong significantli life span mice orthotop vivo model a549 combin anti-igf-ir antibodi anti-egfr antibodi superior vinorelbin combin present result indic human anti-igf-ir antibodi h7c10 great potenti cancer therapi combin chemotherapeut agent antibodi target growth factor receptor epiderm growth factor receptor
purpos 17-demethoxi 17-[[ 2-dimethylamino ethyl]amino]geldanamycin 17dmag nsc 707545 water-solubl analogu 17- allylamino -17-demethoxygeldanamycin 17aag compound current clinic trial preclin studi character 17dmag concentr plasma normal tissu tumor i.v deliveri mice correl tumor normal tissu 17dmag concentr alter heat shock protein hsp90 select hsp90-chaperon protein method specifi time i.v administr mg/kg 17dmag scid mice bear s.c mda-mb-231 human breast xenograft kill plasma tissu retain 17dmag concentr determin hplc raf-1 heat shock protein hsp70 hsp90 tissu determin western blot result peak plasma 17dmag concentr 15.4+/-1.4 microg/ml area under plasma 17dmag concentr versu time curv 1072 microg/ml min correspond total bodi clearanc ml/kg/min peak 17dmag concentr liver 118.8+/-5.7 microg/g kidnei 122.9+/-10.6 microg/g heart 81.3+/-8.1 microg/g lung 110.6+/-25.4 microg/g occur 5-10 min peak concentr spleen 70.6+/-9.6 microg/g tumor 9.0+/-1.0 microg/g occur 30-45 min 17dmag detect tumor normal tissu raf-1 tumor 17dmag-treat mice kill lower tumor vehicl-treat mice hsp90 hsp70 tumor 17dmag-treat anim significantli lower tumor control anim hepat raf-1 decreas time 17dmag treatment howev hepat hsp90 affect hsp70 undetect liver vehicl-treat mice mice kill 17dmag treatment detect liver 17dmag affect renal raf-1 contrast renal hsp70 hsp90 decreas 17dmag treatment renal hsp70 increas approxim twofold kidnei vehicl-treat control mice hsp90 rel protein concentr differ control conclus plasma pharmacokinet 17dmag tumor-bear mice similar previous report nontumor-bear mice 17dmag distribut wide tissu retain longer tumor normal tissu raf-1 hsp90 hsp70 alter differ degre tumor liver kidnei 17dmag-treat anim data illustr complex natur biolog respons 17dmag
prospect studi show high serum level androgen estrogen associ increas incid postmenopaus breast cancer aim present analysi studi prognost valu serum testosteron estradiol relat factor postmenopaus breast cancer patient on hundr ten patient clinic recurr includ studi 5.5 year follow-up patient develop distant metastasi local relaps contralater breast cancer risk advers event relat hormon level examin cox' proport hazard model adjust hormon receptor statu stage diagnosi bodi mass index serum level testosteron estradiol glucos significantli higher patient recur hazard ratio 1.8 0.5-6.3 middl 7.2 2.4-21.4 upper tertil baselin testosteron distribut hormon minor influenc prognosi high testosteron predict breast cancer recurr studi requir determin whether dietari medic intervent reduc testosteron reduc recurr breast cancer
estrogen suggest trigger breast cancer develop via initi mechan involv metabolit catechol estrogen examin hypothesi carri multigen case-control studi 469 incid breast cancer patient 740 healthi control defin role import gene involv differ metabol step protect potenti harm effect metabol studi gene involv detoxif conjug reaction involv methyl catechol-o-methyltransferas comt sulfat sulfotransferas 1a1 sult1a1 glucuronid udp-glucuronosyltransferas 1a1 ugt1a1 on manganes superoxid dismutas mnsod involv protect reactiv oxid speci-mediat oxid convers ce-semiquinon ce-sq ce-quinon ce-q glutathion s-transferas superfamili gstm1 gstt1 involv ce-q metabol support hypothesi came observ trend increas risk breast cancer women harbor greater number put high-risk genotyp gene &lt 0.05 associ stronger signific women suscept estrogen [no histori pregnanc older year first full-term pregnanc fftp iii risk associ have on high-risk genotyp same women have experienc differ menarch-to-fftp interv signific women have expos estrogen longer period year befor fftp furthermor becaus ce-q attack dna lead format doubl-strand break dsb examin whether relationship cancer risk genotyp polymorph ce-metabol gene modifi genotyp dsb repair gene found joint effect ce-metabol gene on two dsb repair pathwai homolog recombin pathwai significantli associ breast cancer develop base comprehens metabol gene profil studi provid support hypothes breast cancer initi estrogen exposur increas estrogen exposur confer higher risk breast cancer caus dsb dna
object studi analys us diagnost mammographi among nonattend attend organis mammographi screen denmark 2000 assess contamin organis screen noninvit ag group measur impact local polici opportunist screen data diagnost mammographi perform denmark 2000 data women target organis mammographi screen programm copenhagen counti fyn collect data link danish person identif number inform offici polici 2000 regard opportunist screen collect counti proport women us diagnost mammographi 1-3 both attend nonattend organis mammographi screen significantli higher copenhagen fyn due avail mammographi privat clinic proport women us diagnost mammographi vari 1-4 across counti offici polici access diagnost mammographi contamin organis mammographi screen adjac ag group impact us instead urbanis posit correl us diagnost mammographi conclus result clearli show nonattend organis mammographi screen programm seek mammographi outsid programm posit polici opportunist screen effect result add evid exist knowledg reason wai achiev high mammographi coverag through well-organis screen programm
investig whether combin zoledron acid doxorubicin induc apoptosi breast prostat cancer cell line synergist interact present investig whether level cell death alter depend sequenc drug administ possibl mechan action respons increas cell death combin treatment breast prostat cancer cell treat zoledron acid alon doxorubicin alon drug sequenc doxorubicin befor zoledron acid level apoptot death determin evalu nuclear morpholog found clinic relev concentr doxorubicin zoledron acid induc sequenc- schedul-depend apoptosi breast prostat cancer cell maxim apoptosi cell pretreat doxorubicin befor immedi treatment zoledron acid observ characterist featur cell cycl phase-specif synergist effect replac zoledron acid nonnitrogen-contain bisphosphon clodron induc increas apoptosi induct apoptosi mainli via inhibit mevalon mva pathwai addit mva pathwai intermediari geranylgeraniol inhibit induct apoptosi doxorubicin follow zoledron acid conclus combin treatment breast prostat cancer cell line clinic relev dose doxorubicin zoledron acid induc apoptosi synergist fashion find relev clinic set particularli breast cancer patient receiv drug adjuv set
purpos surfac bone-seek radiopharmaceut rhenium-188-hedp 188re-hedp samarium-153-edtmp 153sm-edtmp investig determin efficaci toxic pain palliat bone metastas method effect treatment 188re-hedp 153sm-edtmp pain symptom life qualiti bone marrow function obtain patient prostat breast cancer patient treat 188re-hedp 3194+/-387 mbq patient 153sm-edtmp 2940+/-545 mbq 188re-hedp group includ patient patient 153sm-edtmp group patient patient breast prostat cancer respect patient interview us standard set question befor therapi week blood count taken weekli week week result treatment 188re-hedp patient report pain relief 153sm-edtmp sixteen percent patient treat 188re-hedp given 153sm-edtmp discontinu analges pain free patient describ improv karnofski perform scale 73+/-7 85+/-8 week 188re-hedp p&lt 0.05 68+/-9 74+/-9 153sm-edtmp 0.217 patient post-188re-hedp patient post-153sm-edtmp show thrombocytopenia 100 /microl maximum nadir platelet leukocyt count observ second fourth week treatment both revers week signific differ pain palliat karnofski perform scale bone marrow toxic lower beta energi 153sm-edtmp higher beta energi 188re-hedp 0.098-0.442 conclus both radiopharmaceut effect pain palliat induct sever side effect signific differ therapeut efficaci toxic
purpos e-cadherin express divers differ patient characterist produc variabl express wherea studi indic downregul e-cadherin associ loss cellular adhes correl poor prognosi metastasi studi fail confirm present studi us highli homogen popul patient high-risk breast cancer basi ethnic socio-econom statu examin relationship e-cadherin prognost marker breast cancer method immunohistochem stain undertaken estrogen progesteron receptor epiderm growth factor receptor her-2 p53 vascular endotheli factor vegf hypoxia induc factor 1alpha hif-1alpha level marker compar e-cadherin express high-risk african-american patient popul result e-cadherin express persist later stager diseas strongli associ her-2 hif-1alpha express p53 er/pr vegf conclus contrast studi heterogen popul e-cadherin preserv aggress tumor high-risk popul ethnic socio-econom risk stratif need account studi correl marker prognosi
purpos adam disintegrin metalloproteas multifunct membran-bound cell surfac glycoprotein numer function cell growth differenti motil wish investig express adam human breast cancer method express adam determin breast cancer specimen correspond non-neoplast breast tissu patient mcf-7 mda-mb 453 breast cancer cell line via quantit rt-pcr immunohistochemistri effect anti-adam antibodi cell prolifer assess measur dna-synthesi result breast cancer tissu sampl show increas mrna express adam wherea adam differ express protein express studi immunohistochemistri adam express mcf-7 mda-mb453 cell line highest express level observ adam applic anti-adam anti-adam antibodi significantli inhibit prolifer both mcf-7 mda-mb453 breast cancer cell line contrast growth mcf-7 cell appear stimul administr anti-adam antibodi conclus result studi suggest adam differenti express human breast cancer capabl modul tumour cell growth
gene product spleen tyrosin kinas syk implic suppress breast cancer invas previous report syk express lost subset breast cancer primarili methyl-mediat gene silenc studi explor possibl us dna methyltransferas inhibitor 5-aza-2'-deoxycytidin aza suppress breast cancer cell invas restor syk express found aza treatment reestablish express syk accompani suppress invas capac syk-neg cell invas inhibit due global cellular toxic treatment affect overal cell prolifer decreas invas aza treatment diminish piceatannol syk inhibitor suggest syk plai signific role aza-induc invas suppress syk promot hypermethyl found infrequ patholog normal mammari tissu benign lesion &lt contrast syk methyl frequent identifi ductal carcinoma situ approxim invas ductal carcinoma node-neg node-posit case indic hypermethyl syk occur stage prior develop invas phenotyp result suggest potenti us syk methyl valuabl biomark detect earli cancer lesion support us aza reagent manag advanc breast cancer
receptor tyrosin kinas plai import role malign transform epitheli cell activ signal transduct pathwai import prolifer invas metastasi pilot studi evalu express c-met her2/neu receptor tyrosin kinas c-met ligand hepatocyt growth factor/scatter factor hgf/sf primari breast cancer lymph node metastas us both convent immunohistochemistri confoc immunofluoresc neither c-met hgf/sf nor her2/neu express correl establish prognost factor ag lymph node involv estrogen receptor progesteron receptor tumor size grade both stain method confirm signific correl c-met overexpress high risk diseas progress furthermor among tumor c-met overexpress overexpress her2/neu identifi subset patient aggress diseas addit her2/neu median diseas-free surviv patient c-met overexpress tumor month compar month c-met express low 0.037 3.0 signific impact c-met tumor aggress independ her2/neu confirm multivari analysi conclus role c-met express prognost variabl consequ interest target novel therapeut approach deserv analysi larger cohort patient
chek2 kinas tumor suppressor activ respons dna doubl-strand break contribut cell cycl arrest apoptosi c.1100delc mutat associ famili breast cancer tumor mutat carrier show reduc absent chek2 protein express here studi chek2 protein express immunohistochemistri tissu microarrai 611 unselect breast tumor evalu tumor characterist among 297 unselect breast cancer patient defin c.1100delc germ line mutat statu 2.5 carrier frequenc chek2 protein express reduc 21.1 unselect breast cancer studi tumor reduc chek2 express larger primari tumor size pt3-4 nomin signific 0.002 compar tumor normal stain similar trend larger tumor size among breast tumor c.1100delc germ line mutat carrier tumor c.1100delc mutat carrier higher grade noncarri nomin signific 0.02 c.1100delc germ line mutat associ strongli bilater breast cancer signific correl chek2 statu hormon receptor statu histolog lymph node statu overal surviv
promin phenotyp plasmin defici mice reduc metastasi mmtv-pymt transgen breast cancer model proteolyt activ plasmin gener inact plasminogen on activ upa tpa find upa defici alon significantli reduc metastasi 7-fold mmtv-pymt model studi cohort mmtv-pymt transgen mice upa-defici wild-type control tumor incid latenc growth rate final primari tumor burden significantli affect upa defici contrast averag lung metastasi volum reduc 1.58 wild-type control 0.21 upa-defici mice 0.023 tumor cell dissemin brachial lymph node reduc 28/53 wild-type control 17/54 upa-defici mice 0.032 mice plasminogen displai sever pleiotrop phenotyp comparison spontan phenotyp modest upa-defici mice probabl becaus still activ tpa show metastasi strongli select decreas upa-defici mice suggest upa-direct antimetastat therapi efficaci limit side effect
molecular background sporad endometri cancer coexist colorect breast cancer clear investig microsatellit instabl msi statu mismatch repair mmr gene product mlh1 msh2 msh6 sporad endometri cancer coexist colorect breast cancer sixteen sporad endometri cancer colorect cancer sporad endometri cancer breast cancer endometri cancer coexist cancer control analyz highest frequenc msi among group control incid low-frequenc msi significantli higher among endometri cancer case diagnos befor ag high-frequenc msi msi-h case belong interestingli incid msi-h significantli higher tamoxifen-non-treat case treat case result suggest alter mmr gene appear involv carcinogenesi seem uncommon presenc msi sporad endometri cancer us marker predict risk colorect cancer
purpos studi evalu efficaci somatostatin receptor scintigraphi sr imag metastas patient advanc breast cancer assess relationship exposur chemotherapi hormonotherapi overexpress somatostatin receptor ss-r breast cancer cell surfac twelv patient metastat breast cancer intraven i.v inject in-111 pentatreotid 120 mbq earli later imag obtain doubl-head gamma camera equip medium-energi collim spect perform need imag result compar comput tomographi bone scan uptak level evalu site-specif visual analysi metastat breast cancer visual sr global sensit imag specif correct predict tumor absenc 100 sensit significantli higher bone lung metastas sr result relat express ss-r metastat cell surfac evid relationship biolog characterist primari drug exposur seri sr quantit analysi demonstr tumor metastas differ greatli uptak level fifteen percent metastat site seri show strong uptak data support import specif sr identifi metastas mostli case bone lung diseas well role sr predict respons metastat cell treatment somatostatin analogu ss-rs overexpress cell surfac result confirm larg scale studi sr show potenti treat select patient overexpress ss-r tumor cell design target therapi analogu
inhibin inh dimer glycoprotein compos alpha-subunit inh-alpha on two possibl beta-subunit inh-betaa -betab aim studi determin frequenc tissu distribut inh-alpha -betaa -betab breast cancer tissu paraffin-fix ductal carcinoma situ dci invas ductal carcinoma lymph node metastas idc infiltr ductal carcinoma lymph node metastas idc/ln primari ductal carcinoma subsequ recurr analyz immunohistochem mean monoclon antibodi inhibin-alpha -betaa -betab subunit inh-alpha observ dci 5/7 express significantli higher dci idc 1/7 p&lt 0.05 idc/ln 0/8 p&lt 0.005 recurr breast cancer tissu 0/7 p&lt 0.005 inh-betaa subunit demonstr dci case significantli higher intens compar idc p&lt 0.05 idc/ln p&lt 0.01 primari carcinoma subsequ recurr p&lt 0.05 inh-betaa express signific higher primari tumor subsequ recurr compar idc/ln p&lt 0.05 metastat lymph node express lowest inhibin-betaa compar group p&lt 0.01 inh-betab demonstr mammari carcinoma tissu statist differ differenti express inh-alpha dci suggest function tumor suppressor breast tissu suggest us marker recogn patient subsequ risk develop invas ductal cancer higher inh-betaa express dci invas cancer suggest import role mammari carcinogenesi interestingli primari breast tumor subsequ recurr express higher intens inhibin-betaa subunit suggest import role metastat pathogenesi util tumor marker immunoreact inhibin-betaa significantli higher dci invas ductal carcinoma suggest import role mammari carcinogenesi metastat lymph node express lower inh-betaa -betab primari tumor caus differenti aggress tumor cell primari tumor inhibin/activin subunit us prognost marker breast cancer
studi effect ici 182780 bi ethyl norspermin be-3-3-3 cell growth apoptosi estrogen receptor-posit mcf-7 breast cancer cell combin treatment 100 ici 182780 microm be-3-3-3 dai inhibit cell growth 74.3+/-8.4 mcf-7 cell compar 25.4+/-5.8 45.8+/-12.2 respect ici 182780 be-3-3-3 us singl agent treatment 100 ici 182780 microm be-3-3-3 singl agent result 9.1+/-1.0 35.1+/-4.5 apoptosi respect measur apo-brdu assai ici 182780 be-3-3-3 us combin percentag apoptosi 60.6+/-3.8 improv efficaci ici 182780 be-3-3-3 combin growth inhibit observ t-47d cell western blot analysi show combin ici 182780 be-3-3-3 caus down-regul anti-apoptot bcl-2 bcl-xl protein increas level pro-apoptot bax protein combin treatment increas caspas-8 activ analysi polyamin level combin treatment show spermidin spermin level down regul significantli studi indic potenti effect combin strategi breast cancer treatment result link down-regul polyamin pathwai apoptot cell death regul mediat cell death
radiotherapi wide us treatment breast cancer reduc risk loco-region recurr overexpress erbb2 receptor occur 20-30 breast cancer seem involv chemotherapeut resist breast cancer cell radioresist lung cancer cell hypothesi studi erbb2 confer resist radiat-induc apoptosi breast cancer cell through phosphatidylinositol 3-kinas pi3-k /akt signal pathwai two human breast cancer cell line us bt-474 mcf-7 bt-474 cell overexpress erbb2 mutat p53 mcf-7 normal express erbb2 function p53 cell treat pi3-k inhibitor wortmannin erbb receptor ligand heregulin-beta1 express both malign stromal cell vivo pharmacolog treatment cell irradi gamma-radiat consist p53 statu cell line gamma-radiat caus arrest mcf-7 cell bt-474 cell gamma-radiat increas apoptosi averag 44-109 mcf-7 treatment mcf-7 heregulin-beta1 decreas apoptosi 48-84 compar untreat control bt-474 cell wortmannin combin radiat result 119 76-161 apoptosi compar wortmannin alon wherea radiat alon result 15-75 increas apoptosi radiosensitis effect mcf-7 furthermor transfect mcf-7 cell constitut activ akt made cell resist apoptosi taken togeth result support hypothesi erbb2/pi3-k/akt signal pathwai involv resist radiat-induc apoptosi breast cancer cell signal pathwai overstimul
high level express urokinas plasminogen activ upa well document varieti tumor breast cancer express upa essenti tumor cell invas metastasi prolifer contrast primari object tumor therapi reduc upa express level tumor result abrog prolifer invas metastas tumor cell investig effect upa mda-mb-231 cell line mda-mb-231 cell highli invas express high level upa studi upa inhibit achiev two methodolog stabl transfect antisens upa vector transfect sirna molecul small interf rna plasmid vector construct clone upa-specif cdna 612 fragment pbk-cmv plasmid antisens orient contrast doubl-strand 21-mer sirna design target upa antisens-transfect cell reveal decreas upa mrna protein detect real-time pcr immunocytochemistri elisa western blot moreov transfect cell exhibit significantli reduc prolifer activ determin fluorometr prolifer assai conclus studi sirna-techniqu superior method regard time save clone select instant avail transfect cell moreov both strategi lead upa suppress stronger inhibitori effect obtain applic sirna-base techniqu
investig shown pc-spe potent herbal mixtur us prostat cancer patient studi examin inhibitori effect certain individu compon pc-spe vitro prolifer human breast cancer cell mda-mb231 human umbil vein endotheli cell huvec data show individu compon pc-spe vari suppress effect cellular prolifer rabdosia rubescen appear most potent agent assai apoptosi up-regul rabdosia rubescen caspas-9 tunel assai effect mediat via both mapk mitogen-activ protein kinas akt kinas pathwai mous experi extract rabdosia rubescen suppress breast cancer xenograft size decreas tumor vessel densiti conclud rabdosia rubescen potenti us treat prevent breast cancer extract herbal sourc deserv studi
myoepithelium integr part mammari ductal lobular architectur posit lumin cell basement membran describ first report cytogenet find adenomyoepithelioma breast balanc p23 q21 provid gene express profil us affymetrix genechip u95av2 affymetrix santa clara differenti analysi identifi 857 gene 2-fold mrna chang comparison pool normal breast control immunohistochem analysi us confirm result limit number gene express result group base chromosom locat gene associ protein function identifi sever potenti pathogenet mechan autocrin paracrin growth stimuli develop myoepitheli tumor
previous character experiment system role candid metastasi-relat gene screen test monoclon cell line m4a4 nm2c5 origin mda-mb-435 breast tumor cell line opposit metastat capabl vivo investig gross genet chang present model perform detail molecular cytogenet evalu parent cell line m4a4 nm2c5 cell line relat clone metastat phenotyp us combin spectral karyotyp sky g-band fluoresc situ hybrid fish abl resolv ident common marker chromosom present mda-mb-435 cell defin sever chromosom chang specif monoclon cell line twenti ident structur numer chromosom aberr includ trisomi chromosom well present cell line major transloc rel simpl non-reciproc rearrang most frequent involv chromosom chromosom gain 20q common alter breast cancer metastat m4a4 cell line contain numer uniqu chromosom aberr abnorm band region chromosom abr best clone-specif identifi convers q22 q26.1 found exclus non-metastat nm2c5 cell line integr karyotyp data cytogenet genom databas will enhanc abil identifi gene plai critic role cancer develop progress
few case breast cancer neurofibromatosi type nf1 report literatur here present famili histori neurofibromatosi breast cancer hereditari nf1 mutat observ case loss heterozygos loh analys breast tumor reveal loh nf1 region famili proband mother breast cancer proband diagnos breast cancer ag year brca1 brca2 mutat observ proband's peripher blood dna nor mutat observ immunohistochem analyz paraffin block tumor dna neurofibromin encod nf1 gene region report absent human breast cancer-mda-mp-231 cell neurofibromin similar function gtpase activ protein gap p120 gap acceler inactiv ra oncogen molecular alter nf1 gene region caus neurofibromatosi loh tumor tissu case support role nf1 gene etiolog case breast cancer
adjuv treatment still work small percentag breast cancer patient strategi need develop immunotherapi promis approach becaus successfulli attack tumor cell stage dormanc assess feasibl us allogen approach vaccin breast cancer patient select cd80-transfect breast cancer cell line base immunogen properti us cd80+ breast cancer cell human leukocyt antigen hla -a*02-match peripher blood mononuclear cell pbmc breast cancer patient allogen mix lymphocyt-tumor cell cultur mltc possibl isol hla-a*02-restrict cytotox cell ctl furthermor genet modifi variant express influenza matrix protein serv surrog tumor-associ antigen taa abl stimul flu peptid-specif cell alongsid induct allorespons mltc breast cancer cell demonstr express alreadi known taa cea muc-1 mage-1 mage-2 mage-3 improv antigen her-2/neu ad panel marker antigen known elicit hla-a*02-restrict ctl patient breast cancer antigen-process antigen-present capac cell demonstr stimul her-2/neu-specif cd8+ cell pbmc breast cancer patient vitro result gave good rational phase i/ii trial cd80+ her-2/neu-overexpress variant actual us cellular vaccin patient metastat breast cancer proof principl present data two patient signific increas interferon-gamma ifn-gamma releas detect postvaccin pbmc stimul allogen vaccin cell well hla-a*02-restrict her-2/neu epitop whole cell vaccin trial monitor particularli challeng becaus strong allorespons limit knowledg taa studi panel her-2/neu epitop togeth quantit real time qrt -pcr method analyz vaccin-induc cytokin secret cell prove highli sensit feasibl perform immunolog stage vaccin
cd46 membran cofactor protein mcp complement regulatori protein identifi nucleat cell protect attack autolog complement breast carcinoma report consist express cd46.aim method previou immunohistochem studi show breast carcinoma loss cd59 cd55 correl poor surviv studi aim investig prognost signific cd46 breast tumour us rabbit polyclon anti-cd46 antibodi standard immunohistochemistri method total 510 breast tissu patient primari oper breast cancer diagnos 1987 1992 previous includ tissu microarrai includ patient year ag mean year long-term follow-up median month result immunohistochem studi reveal 507/510 99.4 breast tumour express cd46 strong immunoreact exhibit 136/510 tumour moder weak stain observ tumour respect intens cd46 express significantli associ tumour grade &lt 0.05 histolog type tumour &lt 0.001 tumour recurr &lt 0.05 correl lymph node stage presenc vascular invas nor patient ag menopaus statu interestingli most tumour express cd46 appear poor-prognosi tumour lose cd55 cd59 still express cd46.conclus breast tumour express high level cd46 correl tumour grade recurr like loss cd55 cd59 compens express cd46 howev loss cd55 cd59 tumour still express cd46 still associ poor prognosi suggest cd46 alon protect complement lysi loss cd55 cd59 associ role immun regul
tamoxifen tam wide us treatment prevent breast cancer tam metabol cytochrom p450 cyp450 enzym includ cyp3a5 two genet polymorph cyp3a5 known cyp3a5*3 cyp3a5*6 effect polymorph tam metabol tam side effect tumor characterist unknown work test hypothesi cyp3a5 polymorph associ differenti tam level tam side effect tumor characterist breast cancer patient postmenopaus women breast cancer recruit singl cancer center polymorph statu establish us polymeras chain reaction pcr associ polymorph statu race tam level side effect tumor characterist assess us t-test logist regress model data indic 40.7 breast cancer patient cyp3a5*3 polymorph 9.1 cyp3a5*6 polymorph addit caucasian women time like carri cyp3a5*3 polymorph african american women wherea women nine time like carri cyp3a5*6 polymorph caucasian women signific differ tam tam metabolit level tam side effect polymorph statu signific differ howev mean tumor size women cyp3a5*6 polymorph 3.6+/-0.98 compar polymorph 2.0+/-0.18 p&lt 0.02 taken togeth data suggest racial differ cyp3a5 polymorph exist polymorph appear associ level tam metabolit side effect
regul secret angiogen factor cxcl8 vascular endotheli growth factor vegf determin breast tumor cell monocyt cell host cell contribut breast cancer cxcl8 secret partli secret vegf up-regul monocyt cell breast tumor cell chemokin ccl5 ccl2 egf potent up-regul cxcl8 secret breast tumor cell effect promot consecut treatment cell estrogen progesteron find provid evid complex set pro-malign factor control express angiogen mediat breast tumor site
estrogen associ epidemiolog risk factor invas breast cancer cell express estrogen receptor er epitheli hyperplasia lack atypia ehla influenc breast cancer progress conduct nest case-control studi 268 women biopsi-confirm ehla determin whether immunohistochem express eralpha ehla affect subsequ breast cancer risk studi subject prior current histori breast cancer atyp hyperplasia immunohistochem stain individu lesion adjac normal lobul consid posit epitheli cell stain eralpha risk invas breast cancer ehla patient eralpha-posit normal lobul twice ehla patient 1.0-3.8 risk affect eralpha statu ehla lesion eralpha express adjac normal lobul increas moder breast cancer risk previous associ ehla
malign breast cancer estrogen metabol alter favor accumul hydroxyestradiol gener free radic reactiv speci activ matrix metalloproteinas mmp turn hydrolyz protein extracellular matrix ecm act barrier tumor cell passag aim studi determin whether reactiv oxygen speci gener 4-hydroxyestradiol 4-oh activ mmp-2 enhanc invas breast cancer cell mda-mb-231 vitro enzymat assai gel zymographi demonstr 4-oh concentr low led convers prommp-2 activ mmp-2 activ prommp-2 4-oh inhibit zn-sod support involv free radic superoxid anion us invas chamber coat matrigel artifici ecm 4-oh enhanc invas mda-mb-231 breast cancer cell 3-fold addit zn-sod reduc invas mda-mb-231 cell 2-fold support involv gener 4-oh addit mmp-2 inhibitor complet inhibit enhanc invas induc 4-oh demonstr import activ mmp-2 4-oh hand estradiol doe catechol structur gener free radic activ prommp-2 enhanc invas beast cancer cell data need confirm anim model studi suggest accumul 4-oh breast tumor enhanc invas breast cancer cell
proteom emerg field medic scienc focus librari protein specif given biosystem proteom understand relationship therein field incorpor technolog appli serum tissu order extract import biolog inform aid clinician scientist understand dynam biologi system interest patient cancer tool includ laser captur microdissect tissu lysat arrai mass spectrometri approach technolog potent coupl advanc bioinformat analysi us character content chang proteom induc physiolog chang benign patholog applic tool assist discoveri biomark lead diagnost test improv therapeut tool addition provid molecular character cancer allow individu molecular therapi understand basic concept tool us will illustr best appli technolog patient benefit earli detect cancer improv patient care
purpos defin maximum-toler dose mtd evalu dose-limit toxic dlt combin capecitabin vinorelbin patient metastat breast cancer relaps adjuv first-line treatment addit aim obtain data efficaci safeti recommend dose patient method patient measur metastat breast cancer failur prior chemotherapi includ anthracyclin taxan elig capecitabin administ fix dose 1000 mg/m oral twice daili week follow week rest on treatment cycl consist week treatment contain two treatment period capecitabin vinorelbin given intraven escal dose mg/m dose level mg/m dose level dai result thirti-three patient receiv total cycl capecitabin vinorelbin median number administ cycl per patient three rang on six thirti-on patient evalu toxic dose level four seven patient experienc dlt nausea/vomit febril neutropenia grade neutropenia infect diarrhea mtd defin order confirm safeti efficaci dose level extend patient two patient [8.3 confid interv show dlt hospit due febril neutropenia prolong neutropenia main toxic neutropenia observ nation cancer institut common toxic criteria grade patient overal respons rate capecitabin vinorelbin 72.7 includ three patient complet remiss median time diseas progress month 4.3-11.7 overal surviv 19.2 month 11.3-27.1 base intent-to-treat analysi conclus combin capecitabin vinorelbin administ manag toxic show signific efficaci patient metastat breast cancer failur anthracyclin- taxan-base therapi
object non-steroid select estrogen receptor modul tamoxifen current most extens us hormon agent prevent treatment estrogen receptor-posit breast cancer epidemiolog studi clinic trial shown increas risk endometri cancer tamoxifen exposur howev few studi examin tumor molecular level sought elucid molecular genet alter found tamoxifen-associ endometri cancer method twenti-nine breast cancer patient histori tamoxifen us subsequ develop endometri cancer retrospect identifi match endometri histolog subtyp grade endometri cancer breast cancer patient expos tamoxifen endometri tumor tissu microdissect genom dna extract case direct dna sequenc most commonli mutat gene sporad endometri cancer pten k-ra tp53 ctnnb1 perform addit microsatellit instabl studi fisher's exact test util statist analys result tamoxifen-associ cancer 34.5 contain pten mutat compar 44.8 non-tamoxifen-associ cancer 0.59 pten mutat found tumor endometrioid histolog reflect sporad endometri cancer mutat k-ra tp53 microsatellit instabl present similar frequenc two breast cancer group moreov similar mutat frequenc found sporad endometri cancer conclus tamoxifen non-tamoxifen-associ endometri carcinoma aris women breast cancer contain similar genet alter sporad endometri carcinoma
object estim risk ovarian cancer primari diagnosi breast cancer among women brca1 brca2 mutat identifi host treatment-relat factor modifi risk patient method patient 491 women stage stage breast cancer diagnos 1975 2000 brca1 brca2 mutat identifi patient follow initi diagnosi breast cancer ovarian cancer prophylact oophorectomi death 2002 medic treatment record patholog document review inform abstract medic chart includ date breast cancer diagnosi stage diseas us chemotherapi us radiat therapi usag tamoxifen oophorectomi recurr second malign vital statu result 10-year actuari risk ovarian cancer breast cancer 12.7 brca1 carrier 6.8 brca2 carrier 0.03 us tamoxifen 1.79 0.16 chemotherapi 0.59 0.15 significantli impact risk subsequ ovarian cancer twenti-five percent death women stage breast cancer due subsequ ovarian cancer conclus high incid ovarian cancer suggest oophorectomi recommend femal brca1 brca2 mutat carrier diagnosi breast cancer especi stage diseas breast cancer system therapi significantli alter risk ovarian cancer
growth hormon releas hormon ghrh known multipl anabol effect immun-stimulatori effect previou studi suggest treatment anabol hormon potenti mitig deleteri effect cancer cachexia anim studi effect plasmid-mediat ghrh supplement tumor growth role antitumor immun cell two differ human tumor cell line nci-h358 human bronchioalveolar carcinoma mda-mb-468 human breast adenocarcinoma subcutan implant nude mice ghrh supplement deliveri human ghrh muscl-specif ghrh express plasmid increas tumor progress tumor-bear nude mice male anim implant nci-h358 tumor cell line treat ghrh-express plasmid exhibit decreas size tumor p&lt .02 increas white blood cell p&lt .025 300 increas monocyt count p&lt .0001 well increas frequenc activ cd3+ cd4+ cell tumor compar tumor control anim advers effect observ anim receiv ghrh-plasmid treatment present studi show physiolog stimul ghrh-gh-igf-i axi mice cancer doe promot tumor growth provid viabl treatment cancer cachexia human
breast cancer cell express chemokin receptor cxcr4 frequent metastas organ abund sourc cxcr4 ligand stromal cell-deriv factor sdf-1 chemokin receptor cxcr4 plai activ role metastasi breast cancer here show small interf rna sirna cxcr4 effect downregul cxcr4 express human mda-mb-231 breast cancer cell lead signific decreas breast cancer cell invas adhes found tumor cell lack cxcr4 express prolifer much slower rate control cell vitro surprisingli tumor cell lack cxcr4 express fail grow scid mice repeat experi provid first direct evid essenti role cxcr4 breast cancer growth vivo find suggest expand role cxcr4 molecul tumor cell growth vivo addit role breast cancer metastasi studi impli cxcr4 molecul potenti target control breast tumor growth well metastasi
epha2 receptor tyrosin kinas elev invas human breast cancer major epha2 remain unphosphoryl success attach ligand ephrina1 present surfac adjac cell epha2 initi epha2 phosphoryl lead turnov vivo efficaci variou approach target epha2 breast cancer therapi usual evalu nude mice bear human breast cancer xenograft order establish immunocompet mous model breast cancer epha2-target therapi evalu mous breast cancer cell line mt1a2 epha2 express phosphoryl overexpress epha2 observ mt1a2 cell major remain unphosphoryl signifi epha2 mt1a2 cell behav similar human breast cancer cell human adenoviru subtyp had5 vector express secretori form ephrina1 us vitro vivo target mt1a2-deriv epha2 mt1a2 cell infect had-ephrina1-fc express extracellular domain human ephrina1 attach portion human igg1 heavi chain induc epha2 activ turnov led inhibit mt1a2 cell coloni format soft agar cell viabil monolay cultur addit mt1a2 cell-infect had-ephrina1-fc fail form tumor syngen fvb/n mice least dai postinocul moreov intratumor inocul fvb/n mice-bear mt1a2-induc tumor had-ephrina1-fc slow tumor growth result develop vector-specif immun respons result indic fvb/n mice-bear mt1a2-induc tumor serv immunocompet model breast cancer epha2-target therapeut strategi
promyelocyt leukemia protein pml involv pathogenesi acut promyelocyt leukemia coactiv p53 tumor suppress function abil pml inhibit growth induc cell death solid tumor cell howev determin assai tumor suppressor activ pml compar p53 four liver cancer cell line infect cell replic-defici recombin pml adenoviru exogen pml local nucleu form abnorm enlarg pml-nuclear bodi hour vitro growth curv analysi show overexpress pml initi induc substanti cell cycl arrest trigger massiv cell death test cell line irrespect p53 statu pml-induc cell death decreas presenc broad caspas inhibitor zvad cell death effect pml higher induc p53 longer period time p53 overexpress pml close relat upregul p21 decreas cyclin express unexpectedli retino acid antagon rather enhanc pml-trigger cell death enhanc express adenoviru-cytomegaloviru-promot pml both transcript protein level hour treatment howev pml protein significantli degrad presenc dai 3-5 postinfect pml degrad observ sk-br3 breast cancer cell treat taken togeth find strongli support hypothesi pml act strong independ cell death induc convers abolish therapeut effect pml protein through proteasom degrad protein
background node breast cancer repres case older women current debat whether adjuv therapi women cost-effect purpos evalu adjuv treatment earli-stage node breast cancer hormon therapi chemotherapi combin therapi cost-effect older patient design decis-analysi model us life tabl integr cost treatment dollar impact length qualiti life primari data sourc meta-analysi earli breast cancer trialist' collabor group red book averag wholesal price drug increment cost-effect differ treatment strategi compar map graphic result adjuv therapi cost-effect 65-year-old women earli breast cancer 75-year-old estrogen receptor patient hormon therapi specif tamoxifen cost-effect 530 dollar/qali 75-year-old us chemotherapi cmf 85-year-old us hormon therapi margin cost-effect 000-76 000 dollar/qali efficaci assum ag-insensit similar 65-year-old woman conclus decis-analyt model help polici maker face decis whether support adjuv therapi older breast cancer patient outlin import paramet need consid decis
primari object determin optim dose gemcitabin prolong infus liposom doxorubicin myocet docetaxel primari neoadjuv chemotherapi local advanc breast cancer secondari object includ evalu safeti efficaci regimen patient histolog confirm stage iii breast cancer treat liposom doxorubicin 50-60 mg/m2 docetaxel 60-75 mg/m2 dai gemcitabin 4-h infus 350-400 mg/m2 dai treatment repeat everi week maximum cycl maximum toler dose gemcitabin 350 mg/m2 liposom doxorubicin mg/m2 docetaxel mg/m2 dose-limit toxic stomat diarrhea infect predomin hematolog toxic mild-to-moder myelosuppress grade 3/4 neutropenia cycl non-hematolog toxic gener mild grade toxic observ predomin non-hematolog toxic stomat occur patient grade toxic report stomat nausea diarrhea infect constip case cardiac renal pulmonari neurotox observ clinic respons rate histolog confirm clinic complet remiss occur two patient conclud combin gemcitabin prolong infus liposom doxorubicin docetaxel safe highli effect patient local advanc breast cancer defin maximum toler dose evalu schedul suitabl phase studi
phase trial evalu efficaci toxic vinorelbin mg/m2 plu docetaxel mg2/m administ dai everi week granulocyt coloni-stimul factor support g-csf microg/kg/dai dai 3-7 primari prophylaxi patient histolog confirm metastat breast cancer mbc previous treat anthracyclin adjuv first-line set total patient receiv 352 cycl median rang 2-10 patient includ efficaci safeti evalu intent-to-treat analysi eight patient show complet respons patient show partial respons overal respons rate [95 confid interv 33-60] median durat respons 10.0 month median follow-up 18.0 month median time progress 11.9 month median overal surviv 27.1 month most frequent report grade 3/4 hematolog toxic neutropenia patient cycl febril neutropenia report six patient cycl toxic death report most common grade 3/4 non-hematolog toxic asthenia patient cycl nail toxic patient cycl conclus biweekli docetaxel plu vinorelbin g-csf support activ well toler chemotherapi patient mbc resist anthracyclin g-csf support recommend lower incid sever neutropenia febril neutropenia
object evid pentoxifyllin ptx ciprofloxacin cipro protect patient effect chemotherapi radiat allow drug dose escal studi conduct determin whether oral intraven ptx cipro permit increas dose level oral busulfan fix dose cyclophosphamid patient breast cancer receiv autolog syngen hematopoet cell transplant method sixti-seven patient receiv ptx cipro 150 mg/kg escal dose dose began mg/kg escal mg/kg increment group patient grade regimen- relat toxic rrt observ patient treat higher dose result excess rrt observ mg/kg reach two patient dose level rrt steadi-state concentr css 414 545 ng/ml dose mg/kg averag css 280 ng/ml 0/4 rrt among patient css target 350 ng/ml rrt occur conclus preliminari studi ptx cipro maximum toler dose given 150 mg/kg mg/kg css approxim 300 ng/ml random trial necessari determin whether ptx cipro reduc toxic regimen
peutz-jegher syndrom pj autosom-domin polyposi disord increas risk multipl cancer lkb1/stk11 gene act tumor suppressor respons pj plai role suppress breast cancer low express lkb1/stk11 sporad breast cancer significantli associ shorter surviv here describ pj patient aggress breast cancer carri germlin mutat lkb1/stk11 loss normal allel combin mutat associ poor prognosi patient knowledg first show germlin mutat caus pj combin loss homolog normal allel lkb1/stk11 breast cancer
patient breast cancer respons endocrin therapi larg number cytotox drug will induc respons spite introduct activ drug taxan vinorelbin capecitabin gemcitabin trastuzumab anthracyclin still activ ani--and activ most--drug us treat breast cancer inclus combin treat earli advanc diseas prolong surviv howev caus nausea vomit alopecia myelosuppress mucos cardiomyopathi evid increas dose convent anthracyclin cytotox beyond standard dose will improv outcom schedul import dose determin benefit cytotox us treat breast cancer weekli schedul continu infus 5-fluorouracil doxorubicin advantag intermitt schedul liposom format doxorubicin reduc toxic includ cardiotox theoret effect becaus better target tumor normal tissu both pegyl liposom doxorubicin doxil/caelyx [pld] liposom doxorubicin myocet [npld] appear effect convent doxorubicin much toxic multipl phase phase iii studi pld evalu combin cyclophosphamid taxan vinorelbin gemcitabin trastuzumab npld evalu combin cyclophosphamid trastuzumab both liposom anthracyclin cardiotox convent doxorubicin optim dose pld lower convent doxorubicin npld patient treat pld almost alopecia nausea vomit us associ stomat hand-foot syndrom avoid minim us proper dose-schedul contrast optim dose-schedul npld ident convent doxorubicin toxic profil npld similar convent doxorubicin toxic sever npld better toler convent doxorubicin higher dose
third-gener aromatas inhibitor suppress whole-bodi estrogen product postmenopaus women high specif potenc women hormon-sensit breast cancer three agent letrozol anastrozol exemestan provid import altern endocrin therapi antiestrogen tamoxifen block estrogen activ estrogen receptor treatment advanc metastat breast cancer progress first-line tamoxifen three agent activ basi compar tamoxifen first-line therapi advanc breast cancer phase iii trial letrozol significantli superior tamoxifen primari point median time progress well respons rate clinic benefit rate treatment well toler signific differ median overal surviv advantag letrozol first year lost becaus crossov altern agent diseas progress anastrozol evalu two separ trial design combin analysi overal anastrozol least equival tamoxifen activ clearli superior median time progress subgroup patient hormon receptor-posit diseas treatment gener well toler tamoxifen earli report exemestan significantli better tamoxifen respons rate median time progress overal surviv data yet avail date letrozol appear most effect aromatas inhibitor first-line advanc breast cancer set
third-gener aromatas inhibitor letrozol anastrozol exemestan activ well toler postmenopaus patient hormon-sensit advanc metastat breast cancer first- second-line therapi agent investig neoadjuv therapi local advanc breast cancer adjuv therapi earli breast cancer larg neoadjuv studi letrozol result significantli respons tamoxifen significantli patient becom elig breast-conserv surgeri greater letrozol respons associ high low level estrogen receptor express coexpress erbb-1 erbb-2 neoadjuv anastrozol two studi significantli superior tamoxifen render patient elig breast-conserv surgeri adjuv set arimidex tamoxifen alon combin trial compar year anastrozol versu tamoxifen versu combin month' median follow-up diseas-free surviv significantli improv anastrozol compar arm intergroup exemestan studi switch exemestan year tamoxifen significantli improv diseas-free surviv compar remain tamoxifen year ma.17 trial evalu switch letrozol versu placebo year adjuv tamoxifen letrozol significantli superior placebo diseas-free surviv three aromatas inhibitor adjuv therapi well toler long-term effect bone health lipid monitor ongo trial will better defin optimum us aromatas inhibitor adjuv therapi
five year tamoxifen standard adjuv therapi hormon-sensit earli breast cancer women remain appreci risk recurr year therapi tamoxifen doe appear benefici trial ma.17 design determin whether year tamoxifen switch diseas-free postmenopaus women aromatas inhibitor letrozol year improv diseas-free surviv compar switch placebo rational residu cancer cell becom tamoxifen resist growth stimul minor agonist effect tamoxifen well low estrogen concentr cell particularli sensit tamoxifen withdraw coupl treatment potent suppressor estrogen synthesi first plan interim analysi ma.17 extend adjuv letrozol significantli improv estim 4-year diseas-free surviv overal letrozol placebo &lt .001 irrespect nodal statu recurr reduc compar extent includ event locoregion distant recurr respect primari cancer contralater breast breast cancer death reduc letrozol versu placebo letrozol treatment well toler most advers event mild expect symptom estrogen depriv first demonstr extend adjuv therapi standard tamoxifen postmenopaus women earli breast cancer clinic signific impact outcom
deterior bone health major concern progress treatment patient breast cancer especi postmenopaus women diseas- treatment-associ skelet-relat event includ fractur spinal compress bone pain hypercalcemia malign bisphosphon inhibit osteoclast bone resorpt import agent manag skelet-relat event impact breast cancer-relat bone metastas bone loss long-term estrogen depriv therapi aromatas inhibitor review intraven pamidron becom standard bisphosphon reduc delai skelet complic advanc breast cancer bone metastas potent agent zoledron acid appear least effect anoth agent ibandron activ investig comparison intraven bisphosphon zoledron acid most conveni administ requir short infus effect bisphosphon bone health women earli breast cancer investig singl yearli infus zoledron acid shown significantli increas bone miner densiti osteoporot postmenopaus women reduc biochem marker bone turnov possibl treatment-revers aromatas inhibitor-associ bone loss adjuv therapi breast cancer evalu trial letrozol zoledron acid ad initi onset bone loss fractur
sever adjuv trial evalu aromatas inhibitor postmenopaus women earli breast cancer shown signific improv extens efficaci benefit standard therapi tamoxifen treatment gener well toler diseas-free surviv significantli improv anastrozol versu tamoxifen year adjuv therapi arimidex tamoxifen alon combin trial switch exemestan year tamoxifen compar remain tamoxifen year intergroup exemestan studi switch letrozol placebo year year tamoxifen extend adjuv trial ma.17 analys trial data ongo trial will address optim us aromatas inhibitor adjuv breast cancer set whether agent us place sequenc tamoxifen best order sequenc befor tamoxifen best time switch long-term safeti issu associ aromatas inhibitor treatment toxic effect manag
purpos combin anthracyclin taxan date most activ cytotox treatment option neoadjuv palli therapi breast cancer patient ad trastuzumab cytotox agent improv outcom women human epiderm growth factor receptor her2 -overexpress advanc breast cancer conduct pilot studi preoper epidoxorubicin docetaxel plu trastuzumab outpati patient suffer breast cancer patient method fourteen consecut patient enrol prospect clinic pilot trial preoper treatment consist weekli trastuzumab mg/kg bodi-weight load dose mg/kg/week mainten dose combin weekli epidoxorubicin mg/m2 bodi surfac area [bsa] docetaxel mg/m2 bsa onc week week follow week therapi result patient receiv total cycl median cycl rang 2-3 cycl therapeut regimen outpati epidoxorubicin docetaxel plu trastuzumab well toler major respons preoper therapi regimen demonstr patient lead breast-conserv surgeri patient conclus conclud outpati epidoxorubicin docetaxel plu trastuzumab safe neoadjuv treatment patient suffer breast cancer base favor side-effect activ profil regimen consid clinic trial
previous report cancer chemoth pharmacol 252-258 2000 ucn-01 7-hydroxystaurosporin protein kinas inhibitor under clinic trial anti-cancer agent usa japan enhanc camptothecin-induc cytotox breast cancer cell lack p53 function enhanc mediat abrog arrest tumor cell subsequ studi laboratori reveal combin us both ucn-01 camptothecin induc dna doubl strand break p53 mutant tumor cell normal p53 neg epitheli cell studi report implic p53 growth arrest apoptosi combin treatment human mammari epitheli cell topotecan specif topoisomeras inhibitor ucn-01 experi perform cell normal human mammari epitheli cell hmec wild type p53 hme cell transfect hpv16 protein inactiv p53 hmec/e6 mda231 mammari tumor cell p53 mutat ucn-01 select enhanc cytotox topotecan both mda231 hmec/e6 cell contrast ucn-01 show littl pharmacolog effect hme cell median-effect analysi indic synergist cytotox interact exist ucn-01 topotecan both mda231 hmec/e6 cell wherea normal hme cell growth inhibit addit detail cell-cycl analys reveal ucn-01 abrog s-phase accumul induc topotecan treatment p53 defect mda231 tumor cell hmec/e6 cell chang cell cycl profil normal hme cell observ combin ucn-01 topotecan induc maximum apoptot respons both hmec/e6 mda231 cell hr respect data indic ucn-01 select enhanc topotecan cytotox p53 defect cell through induct apoptot signal pathwai time cours induct cell death same ucn-01 provid modal topotecan-base therapi particularli p53 defect cancer patient
background studi ask women directli inform need format prefer relat breast cancer educ method thirti focu group conduct nationwid young women women color ag older result women want breast cancer messag convinc risk screen critic provid clear detail inform breast cancer breast cancer screen guidelin women prefer receiv inform health care provid media outlet conclus women varieti suggest relat breast cancer educ us develop educ intervent
background nativ american women poor 5-year breast cervix cancer surviv rate compar popul group evalu train program prepar commun health repres chr promot prevent earli detect diseas two question guid evalu chr appropri focu train doe train empow chr indirectli facil educ breast cervix cancer promot screen teach breast self-exam skill american indian alaska nativ women method twenti chr indian health servic region separ employ respond telephon survei consist likert scale multipl option short-answer question analysi reli descript statist measur central tendenc result tenur cultur commun membership abil adapt audienc need set demand chr make appropri train recipi train improv skill us appear increas employ' relianc chr screen promot educ cancer posttrain women hear heed screen messag conclus chr appropri focu train train lead increas screen-relat activ continu expand
platinum compound shown activ broad spectrum human tumor vitro vivo clinic util platinum agent gynecolog gastrointestin cancer particularli oxaliplatin colorect cancer well document platinum agent continu evalu varieti cancer given preclin evid synergi among platinum compound anticanc agent clinic trial explor platinum-base combin therapi yield improv treatment varieti malign recent clinic data chemotherapeut strategi treatment lung breast genitourinari cancer myeloma will present review
cytotox agent adjuv treatment breast cancer avail produc modest result tumor burden low rel lack efficaci attribut part nonspecif current regimen addition evid chemotherapi dose us clinic practic optim potenti compromis outcom threshold dose intens reach variat treatment underscor need return basic chemotherapi administr dose schedul concentr threshold therapeut index patient metastat breast cancer clear dose-respons curv shown agent includ anthracyclin e-max model simplest form assum direct relat dose drug effect us improv dose adjuv treatment breast cancer consist model threshold effect observ treatment both anthracyclin paclitaxel breast cancer evid us dose-dens schedul produc better outcom regimen maintain chemotherapi agent full dose schedul crucial treatment success especi adjuv therapi consequ treatment practic us both dose intens dose compress increas likelihood posit outcom patient breast cancer
goal work aim studi assess period preval identifi predictor us complementari altern medicin cam among women breast cancer patient method cross-section studi 263 women particip qualiti life survei report cam us differ cam user nonus evalu us logist regress result year diagnosi period preval cam us among women breast cancer younger women report usag cam older women associ remot diseas pain psychosoci variabl found involv self-help group activ particip leisur activ associ cam us indic differ patient' abil cope diseas most patient inform cam physician conclus involv self-help group leisur activ associ cam us indic differ patient' abil cope research necessari evalu safeti cam determin valu cam health care
object ibandron third gener bisphosphon inhibit bone resorpt human anim studi studi evalu efficaci safeti ibandron singl agent patient tumor-associ hypercalcemia method open multicent non-control clinic trial conduct patient patient receiv ibandron intraven correct calcium 3.0 mmol/l 2.7 mmol/l receiv ibandron correct calcium 3.0 mmol/l result 100 efficaci two dose group calcium correct effect pronounc 4-mg dose group 2-mg dose group most common advers reaction fever skin itch incid 4.5 conclus ibandron activ patient tumor-associ hypercalcemia advers effect well toler
object report clinic patholog characterist bilater primari breast cancer bpbc comparison unilater primari breast cancer upbc method retrospect databas primari breast cancer patient admit cancer hospit march 1967 through 2003 analyz result total 470 primari breast cancer patient treat among 271 patient bilater primari tumor incid 2.1 most bpbc develop both synchron sbpbc incid rate 0.6 metachron mbpbc incid rate 1.5 diagnos premenopaus women averag ag latter case median time interv occurr 57.6 month median surviv time patient sbpbc mbpbc 29.6 month 27.8 month respect statist differ surviv rate group patient nor menopaus statu relat surviv mbpbc patient occurr second breast cancer taken prognost analysi prognosi bpbc patient wors unilater involv conclus prognosi patient bilater primari breast cancer poor mbpbc patient breast cancer appear on meticul follow-up need resect tumor on side earli detect develop cancer countralater breast especi year
epitheli cell adhes molecul epcam over- novo express carcinogenesi epcam express correl increas prolifer dedifferenti recent report clone 1.1 kilobas fragment upstream epcam gene demonstr specif transcript activ here analyz potenti fragment target gene express fragment us regul express green fluoresc protein gfp hsv-1 thymidin kinas hsv-tk model therapeut gene transfect pepprom-control pepprom-gfp plasmid result express function gfp hsv-tk protein specif epcam-posit cell express level both protein correl amount epcam addition target express hsv1-tk transfer mark sensit ganciclovir treatment epcam-posit hek293-ebna1 skbr3 carcinoma cell epcam promot fragment novel tool allow transcript therapeut gene specif epcam-posit carcinoma
doxorubicin dox encapsul polyisohexylcyanoacryl nanospher pihca-dox circumv p-glycoprotein-mediat multidrug resist mdr order investig whether drug formul abl select mdr cell cultur same wai free doxorubicin doe two human tumour cell line k562 mcf7 grown increas concentr free dox pihca-dox both drug formul select level cell line resist free dox pihca-dox mcf7 sublin select pihca-dox exhibit higher level resist both doxorubicin formul select free doxorubicin differ level overexpress sever gene involv drug resist mdr1 mrp1 bcrp top2alpha occur resist variant mdr1 gene overexpress consist higher free dox-select cell pihca-dox-select cell revers bcrp gene overexpress mrp1 top2alpha gene observ select variant result show sever mechan involv acquisit drug resist drug encapsul markedli alter delai process
twist transcript factor basic helix-loop-helix class suggest oncogen properti report twist express regul wnt/beta-catenin signal both wnt-1 twist contribut mammari tumorigenesi aim studi demonstr express twist wnt-1 wnt-2 human breast cancer tissu examin express patient breast cancer rt-pcr immunohistochemistri rt-pcr twenti-three pair cancer normal breast tissu reveal twist up-regul 69.6 16/23 cancer lesion 21.7 5/23 normal breast tissu wnt-2 up-regul cancer lesion 13.0 3/23 normal breast tissu wherea wnt-1 express both cancer normal breast tissu five case examin immunohistochem analys reveal twist posit express 52.2 12/23 cancer lesion 34.8 8/23 normal breast tissu twist wnt-2 highli express breast cancer tissu suggest both molecul plai import role mammari carcinogenesi
background evalu effect mthfr c677t polymorph interact estrogen exposur breast cancer risk nest case-control studi conduct taiwan materi method total histolog confirm breast cancer case 344 cancer-free control recruit juli 1992 decemb 2000 mthfr c677t genotyp determin pcr-rflp-base assai subject complet in-person interview result signific trend breast cancer relat prolong exposur estrogen prior first full-term pregnanc fftp trend 0.0015 contrast statist signific associ risk breast cancer mthfr c677t genotyp howev significantli elev risk breast cancer predispos mthfr 677t variant genotyp observ women prolong exposur estrogen prior fftp adjust 4.98 2.00-12.43 conclus result studi suggest mthfr 677t variant genotyp per overal associ breast cancer risk sizabl associ observ presenc relev environment exposur
background vegf vascular endotheli growth factor kei factor angiogenesi high tissu vegf level relat poor prognosi breast cancer materi method semi-quantit rt-pcr determin rel express vegf mrna mcf-7 both er-alpha+ er-beta+ mainli er-alpha+ pr+ bcl-2+ egfr- mb-mda-231 er-beta+ pr- egfr- breast cancer cell treat estrogen tamoxifen egf epiderm growth factor result mcf-7 cell line estrogen induc express vegf mrna tamoxifen reduc express estrogen tamoxifen confer signific effect mb-mda-231 cell egf show signific effect mcf-7 mb-mda-231 conclus reduc vegf mrna express mcf-7 cell treat tamoxifen relat antagonist effect tamoxifen er-posit breast cancer antagonist effect relat er-alpha
role sdf-1alpha chemokin-cxcr4 receptor system tumor cell transendotheli migrat studi cultur metastat breast tumor cell line mda-mb-231 mda-mb-435 alon huvec monolay pre-establish transwel filter 24-hour cultur presenc absenc sdf-1alpha tumor cell transmigr rate compar show cxcr4 present both cell line mda-mb-231 mda-mb-435 cell migrat stimul increas concentr sdf-1alpha neutral anti-cxcr4 antibodi inhibit sdf-1alpha chemoattract effect cxcr4 express measur cytofluorometri enhanc treatment sdf-1alpha mda-mb-231 cell remain unchang mda-mb-435 cell scatchard analysi evid 8.10 2.10 high affin site rang respect mda-mb-231 mda-mb-435 cell signific differ explain distinct transendotheli migrat respons two cell line presenc sdf-1alpha
solid tumor develop resist retinoid carcinogenesi on strategi overcom resist includ combin molecul differenti cytotox chromatin-remodel agent analys anti-prolif activ two histon-deacetylas inhibitor hdaci trichostatin tsa sodium phenylbutyr alon combin retinoid all-tran retino acid atra 41-5253 two human breast cancer cell line hormon-depend mcf-7 hormon-independ mda-mb-231 line respond differ retinoid mcf-7 sensit whilst mda-mb-231 rather resist retinoid combin hdaci molecul potenti retinoid activ growth inhibit especi associ 41-5253 tsa fac analysi observ anti-prolif effect partial due pro-apopot mechan suggest cell-cycl block efficaci retinoid/hdaci combin repres strategi breast cancer chemotherapi allow inhibit both er- cell popul
growth invas breast cancer cell adjac distant site associ express metalloproteinas mmp capabl degrad almost extracellular matrix macromolecul support stroma order identifi marker us monitor breast cancer pathogenesi metastat potenti examin express mrna encod mmp endogen inhibitor timp panel four epitheli breast cancer cell line high mda-mb-231 zr-75-1 low mcf-7 bt-20 metastat potenti express compar normal mammari cell mcf-12a express pattern evalu us cell cultur serum-contain serum-free media gene express studi perform cell cultur rna isol revers transcript polymeras chain reaction both normal breast cancer cell express mmp timp variou level depend cell type cultur condit comparison mrna level serum-contain media show mmp-9 mt2-mmp timp-1 highli express cancer cell compar normal on wherea mmp-1 overexpress breast cancer cell high invas potenti serum-free cultur highli metastat cell retain overexpress profil mmp-1 furthermor mt2-mmp timp-1 constitut express correl cancer cell wherea constitut express mmp-9 similar normal cancer cell result studi indic express mmp depend cultur condit i.e growth factor present serum-contain media furthermor data suggest independ cell cultur condit express mt2-mmp associ malign transform mammari cell overexpress mmp-1 highli metastat potenti epitheli breast cancer cell
background serum her2 test allow determin real-time her2 statu breast cancer patient aim investig studi whether chang serum her2 statu occur clinic cours breast cancer evalu prognost signific serum her2 statu time first diagnosi primari breast cancer onset metastat diseas surviv relaps sar materi method her2 serum level retrospect measur 152 breast cancer patient time first diagnosi breast cancer onset metastat diseas enzym immunoassai result twenti-seven 152 patient elev her2 serum level time first diagnosi breast cancer contrast 152 patient show elev serum her2 level metastas diagnos chang serum her2 statu clinic cours observ 152 patient serum her2 statu time first diagnosi breast cancer impact surviv relaps sar 0.4 howev median sar serum her2-posit patient onset metastat diseas significantli shorter month 3-12 compar patient serum her2-neg time month 14-22 &lt 0.01 conclus serum her2 statu chang cours diseas serum her2 statu re-evalu time diagnosi metastat diseas optim treatment decis
background presenc dissemin tumor cell bone marrow breast cancer patient associ poor prognosi relat aggress breast cancer indic tumor biolog clinicopatholog factor aim studi identifi featur primari tumor relat presenc dissemin tumor cell patient method clinic data 508 primari breast cancer patient analyz tumor biolog featur primari tumor includ her2 p53 ki-67 bcl-2 hormon receptor statu well clinicopatholog factor includ histolog menopaus statu lymph node statu tumor size grade studi associ involv univari multivari analysi result two-hundr two 508 primari breast cancer patient dissemin tumor cell p53 express hormon receptor statu her2 ki-67 significantli relat involv multivari analysi reveal p53 express 1.9 1.2 3.0 follow progesteron receptor statu 1.5 1.0 2.2 independ determin involv conclus presenc dissemin tumor cell influenc tumor load reflect tumor size lymph node involv wherea tumor biolog factor independ correl involv result substanti import role tumor biolog factor primari tumor tumor cell dissemin
purpos determin maximum toler dose mtd dose-limit toxic dlt vinorelbin vnr fix dose cyclophosphamid cpm 5-fluorouracil/leucovorin 5-fu/lv patient metastat breast cancer mbc pretreat anthracyclin taxan patient method eighteen patient mbc pretreat anthracyclin taxan enrol vnr administ 10-min intraven infus i.v dai escal dose cpm 300 mg/m2 i.v bolu 500 mg/m2 2-hour i.v infus follow 5-fu 1500 mg/m2 22-hour continu infus c.i two consecut dai treatment repeat everi two week result dose vnr 22.5 mg/m2 rhg-csf mg/m2 rhg-csf support dlt reach grade neutropenia occur six patient fourteen cycl episod febril neutropenia on 5.5 patient develop grade thrombocytopenia grade neurotox occur two patient grade asthenia five conclus recommend dose phase studi mg/m2 vnr 22.5 mg/m2 rhg-csf support 300 mg/m2 cpm dai 500 mg/m2 1500 mg/m2 5-fu dai
view potenti action growth factor evid abnorm high blood level prolactin prl associ poor prognosi metastat breast cancer moreov metastat breast cancer-relat hyperprolactinemia proven counteract efficaci cancer chemotherapi neg influenc high blood level prl efficaci chemotherapi metastat breast cancer confirm previou preliminari studi show concomit administr anti-prolactinem dopaminerg agent bromocriptin enhanc therapeut effect chemotherapi howev clinic us bromocriptin limit short durat gastrointestin toxic anti-prolactinem drug character toxic longer durat activ cabergolin cbg appropri control prl secret breast cancer basi studi plan evalu efficaci toler concomit administr cbg weekli low-dose taxoter txt pretreat metastat breast cancer under chemotherapi studi group compris metastat breast cancer patient femal pretreat least on previou chemotherapeut line contain anthracyclin random treat txt alon txt plu cbg txt mg/m2 given i.v weekli interv least consecut cycl cbg given oral 0.5 onc per week abnorm high pre-treatment level prl 24/70 patient treat txt plu cbg wherea receiv txt alon cbg induc complet normal prl level patient first two week therapi wherea normal prl occur spontan patient treat chemotherapi alon object tumor regress rate significantli higher patient concomitantli treat cbg receiv chemotherapi alon 31/34 13/36 &lt 0.05 differ particularli evid patient high prl level prior therapi 6/11 2/13 cbg-relat toxic occur contrari chemotherapi-induc asthenia significantli lower patient concomitantli treat cbg 5/34 11/36 &lt 0.05 studi show chemoneuroendocrin therapi weekli low-dose txt plu anti-prolactinem drug cbg effect well-toler therapi metastat breast cancer recommend heavili pretreat patient poor clinic statu
background matrix metalloproteinas mmp involv tumour invas metastasi controversi data exist concern prognost valu mmp-9 breast carcinoma examin here whether mmp-9 immunoreact protein correl with--the prognosi breast carcinoma treat hormon adjuv therapi materi method mmp-9 statu determin immunohistochem primari tumour specimen 168 postmenopaus breast cancer patient local advanc diseas treat antiestrogen three year primari therapi result posit immunostain mmp-9 found 61.3 168 primari tumour signific correl clinic stage histolog hormon receptor statu mmp-9 immunoreact correl surviv entir studi popul includ analysi howev compromis diseas-free surviv subgroup patient present estrogen receptor-neg mmp-9-posit tumour 5-year diseas-free surviv patient patient tumour neg both estrogen receptor mmp-9 conclus suggest prognost valu mmp-9 immunoreact primari tumour gener strong breast carcinoma correl clinic benefit antiestrogen therapi mmp-9 posit seem correl earli recurr patient estrogen receptor-neg primari tumour
axillari node statu most import prognost factor patient primari breast carcinoma sentinel node biopsi techniqu receiv much attent possibl altern axillari lymph node dissect aim studi identifi sentinel node periareolar subderm inject radiopharmaceut four point independ tumor topographi presenc biopsi previou surgeri peritumor inject techniqu carri comparison purpos studi perform 115 patient divid group group patient peritumor inject group patient inject four point biopsi studi both imprint cytolog h&amp stain control axillari lymph-node dissect follow patient group posit case group twenti-two twenti-five sn identifi group fals neg sensit specif 100 eighti-two nineti 91.1 sn identifi group lymphoscintigraphi show radiopharmaceut migrat axilla 93.7 case hotspot area 100 time intens background radiat among case neg sentinel node intraop examin histopatholog confirm absenc cancer cell patient wherea posit metastat cell studi show periareolar inject four point seem good lymphat map method identif suggest standard site inject identifi sn studi confirm find ongo
surviv breast cancer patient significantli improv through treatment anthracyclin anthracyclin known produc renal diseas experiment anim littl known toxic anthracyclin clinic relev dose human previou studi cancer patient observ increas urinari activ n-acetyl-beta-d-glucosaminidas nag indic renal tubular cell dysfunct accompani increas urinari zinc loss becaus increas nag activ report treatment anthracyclin hypothes increas urinari nag activ breast cancer patient treat anthracyclin-base regimen will accompani hyperzincuria hypozincemia urinari serum zinc urinari nag serum creatinin examin chemotherapi breast cancer patient treat anthracyclin-base chemotherapi trend increas nag activ compar baselin observ first cycl treatment nag activ significantli elev compar pretreat level on week first third fourth dose chemotherapi serum creatinin concentr decreas significantli second cycl therapi hand urinari serum zinc level chang significantli treatment conclus data confirm presenc mild renal tubular cell dysfunct breast cancer patient treat doxorubicin-base chemotherapi increas urinari nag accompani decreas serum creatinin consist hyperfiltr chang associ abnorm renal zinc handl decreas serum zinc concentr
syndecan-1 cell surfac proteoglycan found predominantli epithelia matur tissu bind both extracellular matrix ecm compon basic fibroblast growth factor bfgf implic restrict growth invas neoplast cell induc adhes capac neoplast cell stroma studi investig breast carcinoma immunohistochem express syndecan-1 protein result assess relat clinicopatholog paramet order clarifi prognost valu possibl relationship hormon receptor content p53 cell prolifer marker extracellular matrix compon estim tissu section 102 breast carcinoma us immunostain perform formalin-fix paraffin-embed tissu section label streptavidin avidin biotin lsab method high express level observ 75/102 73.5 case express immunoreact neoplast cell 67/102 65.7 exhibit high stain intens surviv analysi show increas mortal risk associ high syndecan-1 stain intens borderlin signific 0.041 addit strong neg correl syndecan-1 protein express ecm specif collagen 0.026 tenascin 0.0067 result present studi show implic protein remodel breast cancer tissu through interact extracellular matrix compon probabl influenc tumour progress
irradi convent treatment modal cancer patient howev besid cytotox effect malign cell affect biologi surviv cell overexpress her-2 receptor malign cell prerequisit therapeut efficaci herceptin seem import know whether previou irradi chang overexpress experi perform work aim determin whether x-rai irradi mda-mb-361 mda-mb-453 breast carcinoma cell line besid cytotox action affect overexpress her-2 protein determin cytotox effect x-rai irradi done us trypan blue test breast carcinoma cell respons herceptin treatment presenc fresh human serum healthi volunt's presenc absenc microg/ml herceptin vitro befor cell-irradi evalu mtt test degre her-2 overexpress determin immunocytochemistri us dako herceptest preliminari result obtain work show x-rai irradi besid cytotox effect malign cell lead overexpress her-2 receptor initi immunocytochemistri her-2 neg tumor cell indic chang biologi treat tumor cell investig direct will probabl help elucid task order improv select irradi patient herceptin therapi
report character immunohistochem case primari small cell neuroendocrin carcinoma breast tumor aros left side maximum diamet microscop compos patternless sheet undifferenti small cell high nuclear-to-cytoplasm ratio hyperchromat nuclei indistinct cytoplasm inconspicu nucleoli numer mitot figur larg area coagul necrosi tumor cell posit bcl-2 neuron-specif enolas synaptophysin cam 5.2 cytokeratin ae1/3 neg lca cd30 hmb-45 chromogranin estrogen receptor progesteron receptor her-2/neu cd99 opposit breast harbour intraduct carcinoma focu suggest microinfiltr find report befor paper extens review literatur subject emphas variabl immunohistochem profil aggress mammari small cell carcinoma rapidli fatal clinic cours case appear largest dimens describ literatur underlin import earli diagnosi treatment long-term surviv
background &amp object observ brm-sj antitumor effect clinic practic studi design investig antitumor activ brm-sj mechan action method vitro antitumor experi mtt method meanwhil cell morpholog flow cytometri agaros gel electrophoresi perform determin apoptosi sever tumor cell line result brm-sj antitumor effect human suzhou human glioma shg-44 breast carcinoma mcf-7 human pancrea carcinoma panc1 vitro ic50 valu brm-sj 299 mg/ml 1.853 mg/ml 9.416 mg/ml respect brm-sj shg-44 mcf-7 mark morpholog chang includ cell shrinkag condens chromosom observ electr microscop increas apoptosi shg-44 mcf-7 cell treat brm-sj extract 0.625 -2.5 -48 observ annexin-v/pi flow cytometri analysi agaros gel electrophoresi dna shg-44 mcf-7 cell treat brm-sj extract 1.25 show mark dna ladder pattern conclus antitumor activ brm-sj relat induc apoptosi tumor cell
breast cancer surviv differ percentag point neighbour countri denmark sweden author' aim analys whether caus earli detect sweden extent diseas outcom compar two popul-base breast cancer cohort 1983-1989 breast cancer manag decentr denmark mammographi screen wherea treatment sweden central popul partli screen ten- 15-year rel surviv higher sweden p&lt 0.001 correspond differ crude diseas-specif surviv stage distribut significantli favour swedish cohort multivari analysi ag tumour size extent axillari surgeri spread affect surviv howev impact region persist p&lt 0.001 reanalysi screen-detect patient slightli affect impact region conclud earli detect signific impact surviv region differ import
object studi brca1 mutat chines patient earli onset breast cancer affect rel method genom dna patient' peripher blood mononuclear cell studi us polymeras chain reaction-singl strand conform polymorph pcr-sscp dna sequenc brca1 mutat detect whole gene sequenc result diseas-relat brca1 mutat detect patient studi two patient younger year old on patient famili histori conclus incid brca1 mutat chines patient earli onset breast cancer similar report western countri incid mutat chines breast cancer patient affect rel compar low
object demonstr impact hypoxia er-alpha both breast cancer tissu cell line relationship hypoxia-relat paramet method express er-alpha breast cancer patient posit determin ligand-bind assai examin immunohistochemistri compar ca-ix glut-1 impact hypoxia breast cancer cell line mcf-7 er-alpha posit observ western blot rt-pcr result breast cancer patient er-alpha posit region decreas er-alpha express consist observ peri-necrot region compar distant region both in-situ carcinoma &lt 0.0001 invas carcinoma 0.0001 close associ induct ca-ix glut-1 hypoxia &lt 0.0001 decreas express er-alpha protein mrna breast cancer cell line attribut hypoxia stress factor reduc glucos low product releas necrot hypox cell chronic intermitt hypoxia caus persist down-regul er-alpha mcf-7 breast cancer cell line conclus region hypoxia breast cancer associ reduc er-alpha express intermitt hypoxia caus persist down-regul hypoxia contribut progress er-alpha neg statu potenti develop resist endocrin therapi
object studi express thymidin phosphorylas thymidyl synthas dihydropyrimidin dehydrogenas dpd mrna breast cancer correl prognosi method express level dpd mrna micro-select breast cancer tissu normal breast tissu detect real-time quantit pcr result median express level dpd mrna tumor tissu normal tissu 16.54 0.38 2.47 11.75 0.25 8.33 respect signific differ 0.05 express level dpd mrna show associ tumor size lymph node metastasi patholog grade clinic stage except dpd show neg associ patient' ag signific differ diseas-free surviv overal surviv patient high low dpd mrna level diseas-free surviv tend better patient low mrna level high mrna differ signific 0.069 overal surviv show statist differ 59.00 month 70.30 month 0.0496 conclus express level mrna serv prognost marker breast cancer patient
object analyz clinicopatholog characterist treatment method primari pure squamou cell carcinoma breast method twelv patient primari squamou cell carcinoma breast patholog confirm retrospect review clinic characterist diagnosi treatment prognosi analyz result patient women median ag year 44-76 year patient present singl mass breast present diamet rang 2.5 10.0 diamet patient undergon surgic resect case stage iia iib iiia iiib accord tnm stage system ajcc uicc ten case follow-up month 189 month conclus primari squamou cell carcinoma breast need diagnosi exclus initi confirm fine needl aspir present standard therapi recommend practic prognosi controversi
individu select chemotherapi regimen base molecular characterist cancer desir howev current feasibl develop clinic us predictor respons chemotherapi proven difficult recent novel analyt tool particularli transcript profil shown promis potenti predict test sever small exploratori studi howev practic challeng clinic pharmacogenom same plagu prognost predict marker research decad most import challeng prospect design conduct valid trial demonstr clinic util show improv patient outcom us propos test
introduct limit inform avail trend breast cancer mortal region countri method rate broad ag group calcul 1950 1999 white 1970-1999 black four censu region 508 state econom area unit state result white women ag 50-64 year mortal rel risk [rr] northeast compar south 1.48 1950-1959 1.15 1990-1999 rate increas region 1950s 1960s substanti south increas slightli 1970s region declin slightli northeast midwest west south 1980s declin northeast midwest west south 1990s among similarli ag black women rr northeast compar south 1.13 1.0 1970-1979 1990-1999 respect among women rate increas region 1980s 1990s rate declin northeast midwest west continu increas south conclus histor lower breast cancer mortal rate south erod becaus rel favor trend south
background investig center diseas control prevent cdc nation program cancer registri npcr collabor public health profession seven state district columbia conduct pattern care studi assess qualiti cancer data determin whether stage-specif treatment carri method assess qualiti complet cancer care data unit state train staff pattern care studi abstract medic record obtain detail clinic data treatment tumor characterist stage diagnosi demograph repres sampl patient diagnos breast colon prostat cancer altogeth staff eight particip cancer registri will abstract 500 case breast prostat colon/rectum/anu cancer concord studi addit 150 case local breast cancer 100 case stage iii colon cancer 100 case local prostat cancer pattern care studi chi-squar test will us compar routin registri data re-abstract data investig will us logist regress techniqu describ characterist patient local breast prostat cancer stage iii colon cancer ag race sex type insur comorbid will examin predictor us treatment consist consensu guidelin investig plan us data concord studi determin whether treatment factor reason report differ rel surviv rate unit state europ conclus result methodolog us pattern care studi will provid first time detail inform qualiti complet stage treatment data routin collect state particip npcr will add significantli understand factor determin receipt treatment complianc establish guidelin part concord studi will examin differ surviv among cancer patient breast prostat colon/rectum/anu cancer unit state europ
background tumorigenesi involv alter tumor suppressor gene p53 protooncogen bcl-2 housekeep gene [human mut homologu-2 hmsh2 hypothes mammari carcinogenesi involv interact among p53 bcl-2 hmsh2 protein upper egypt clinicopatholog featur genet chang mammari carcinogenesi unknown method test hypothesi examin issu mastectomi specimen entail normal breast benign prolif breast diseas bpbd duct carcinoma situ dci infiltr ductal carcinoma idc immunostain p53 bcl-2 hmsh2 protein express result averag ag incid ductal carcinoma 43.2 +/- 7.06 year tumor common left right side 1.2 respect 0.05 infiltr ductal carcinoma non-specif type most common histolog type examin averag weight score normal breast bpbd dci idc respect show signific upregul p53 protein 0.00 +/- 0.00 0.00 +/- 0.00 6.25 +/- 2.42 6.62 +/- 2.15 0.001 insignific downregul bcl-2 6.67 +/- 1.33 5.17 +/- 2.20 4.79 +/- 2.27 4.42 +/- 2.83 0.37 signific downregul hmsh2 11.3 +/- 0.75 10.70 +/- 1.27 7.11 +/- 1.50 7.0 +/- 1.33 0.0006 insignific neg correl p53 both bcl-2 -0.20 0.05 hmsh2 -0.15 0.05 protein express conclus upper egypt breast cancer similar clinicopatholog featur high risk region alter p53 bcl-2 hmsh2 protein occur mammari carcinogenesi
radiopharmaceut 99mtc-tetraethylenepentamin tepa -folat synthes introduc tepa gamma-carboxyl group folic acid bind 99mtc high effici ambient temperatur result 99mtc-n5-folat stabl under physiolog condit least radiocomplex tepa known open chain pentamin chelat four-nitrogen act bind site 99mtc folat membran receptor bind 99mtc-tepa-folat establish human tumor cell line u-87mg mda-mb-468 show microm rang normal dmem serum microm folic acid blood kinet studi show clearanc five minut circul cell line tumor mice readili identifi gamma imag reveal major accumul radiotrac liver kidnei intestin high tumor uptak shown tumor bear nude mice tumorto-blood ratio reach 2.68 +/- 0.52 5.5 +/- 1.47 post inject respect surviv fraction obtain clonogen assai 1.02 +/- 0.07 1.03 +/- 0.05 u-87mg mda-mb-468 cell line respect 99mtc-n5-folat conjug promis util receptor specif radiopharmaceut imag neoplast tissu known express folat-bind protein
caveolin-1 princip structur protein caveola sphingolipid cholesterol-rich invagin plasma membran involv vesicular traffick signal transduct caveola-depend signal caveolin-1 act scaffold protein sequest organ multi-molecular signal complex involv divers cellular activ serv paradigm numer diseas process affect ablat mutat caveolin-1 hypothesi caveolin-1 convei tumor/transform suppressor function mammari gland deriv sever independ line evid accumul genet molecular clinic approach human caveolin-1 gene map suspect tumor suppressor locu d7s522/7q31.1 frequent delet human breast carcinoma addit human breast carcinoma harbor domin-neg mutat p132l caveolin-1 gene caveolin-1 rna protein level downregul human primari breast carcinoma cell line reintroduct caveolin-1 vitro suffici inhibit numer tumorigen properti includ anchorag independ growth invas most recent caveolin-1 knockout mice provid breakthrough understand dynam role caveolin-1 pathogenesi mammari epitheli cell hyperplasia tumorigenesi metastasi vivo set review concentr recent advanc implic caveolin-1 breast cancer pathogenesi emphasi signal pathwai regul process
hypomethyl portion genom hypermethyl other frequent attribut human cancer previous show cancer-associ dna hypomethyl involv satellit sat2 main dna compon larg juxtacentromer centromer-adjac heterochromatin chromosom studi compar methyl sat2 centromer satellit dna satalpha well overal genom methyl breast adenocarcinoma known tumor grade stage non-neoplast breast tissu mostli fibroadenoma varieti normal somat tissu control cancer significantli hypomethyl sat2 rel fibroadenoma normal somat tissu satalpha rel normal somat tissu howev unlik sat2 satalpha displai signific differ methyl cancer non-neoplast breast tissu hypomethyl sat2 much better marker breast cancer satalpha hypomethyl signific associ sat2 hypomethyl global dna hypomethyl cancer tumor grade stage axillari lymph node involv hormon receptor statu extens cancer-associ hypomethyl juxtacentromer satellit dna global dna hypomethyl common grade-1 stage-1 carcinoma suggest demethyl genom earli event breast carcinogenesi
e2f1 e2f4 known oppos role cell cycl control present work examin role both e2f1 e2f4 apoptosi induc three cyclin-depend kinas inhibitor roscovitin bm-387032 flavopiridol well three establish chemotherapeut drug vp16 cisplatin paclitaxel find e2f4 level diminish treatment cyclin depend kinas inhibitor flavopiridol roscovitin bm-387032 dna damag drug cisplatin vp16 contrast drug induc e2f1 find mous fibroblast nullizyg e2f4 gene sensit apoptosi induc roscovitin flavopiridol cisplatin vp16 wherea e2f1-defici fibroblast sensit likewis find rnai-mediat reduct e2f4 human cancer cell result increas drug sensit taken togeth result support model e2f1 e2f4 plai oppos role drug-induc apoptosi
absenc estrogen receptor alpha human breast cancer cell indic poor prognosi predict lack respons hormon therapi previou studi laboratori other shown epigenet regul includ dna methyl histon deacetyl common mechan lead gene silenc through us pharmacolog inhibitor 5-aza 2'deoxycytidin aza trichostatin tsa shown alter both mechan result synergist reexpress mrna function protein alter plai larger role stimul cell signal pathwai lead express util newli develop genom wide screen microarrai techniqu identifi gene contribut hormon independ phenotyp aza/tsa mediat express screen identifi confirm express candid gene pp2a xcl1 thy1 nbc4 potenti regul hormon independ phenotyp express two gene xcl1 pp2a appear correl express pp2a express chang degrad us ici 182 780 wherea xcl1 express decreas presenc aza/tsa ici 182 780 suggest pp2a determin express xcl1 appear respons downstream express gene product novel target explor develop therapeut neg breast cancer
consequ increas screen mammographi preinvas breast lesion repres grow percentag breast patholog diagnos intraduct epitheli prolifer breast present classifi three group usual epitheli hyperplasia atyp ductal hyperplasia ductal carcinoma situ boundari two entiti clearli defin morpholog point view clinic manag differ columnar atyp lesion flat atyp hyperplasia frequent observ microcalcif homogen manag lobular lesion classifi under categori lobular neoplasia avoid interobserv variabl molecular biologi data immunoprofil isol differ lobular phenotyp link invas cancer differ system classif differ entiti most recent molecular biologi data controversi consensu describ manuscript
her2-posit statu sole criterion identifi patient breast cancer herceptin trastuzumab therapi accur assess her2 statu essenti ensur patient benefit herceptin correctli identifi sever assai avail determin her2 statu most common routin clinic practic immunohistochemistri ihc fluoresc situ hybrid fish pro con two test upcom method assess her2 statu focu chromogen situ hybrid cish recent approv european commiss describ manuscript import adhes qualiti assur program underlin final differ nation test guidelin discuss
sentinel lymph node biopsi concept describ sever report 1994 technic identif procedur fals neg risk learn curv criteria benefit concern cancer stadif postop morbid assess perop postop patholog examin procedur improv progress remain still under debat classif micro-metastasi isol cell macro-metastasi sentinel lymph node suggest immunohistochim detect prognost impact unclear part discuss articl
benefit provid sentinel lymph node biopsi slnb includ improv patholog examin lower rate sequel aim studi assess accuraci procedur larg tumor march 1999 decemb 2003 663 patient oper breast cancer underw slnb patient tumor larger involv slnb underw complet axillari dissect on hundr sixteen patient 17.5 tumor larger underw identif rate slnb 109/116 among case non metastat slnb neg case 90.7 four case palpabl non sentinel lymph node discov slnb procedur found involv on case lymphoscintigraphi found on lymph node low fixat perform becaus low effici lymphoscintigraphi procedur slnb fals neg rate 1.4 1/72 among case lymph node involv perform case 60.5 same oper time slnb show lymph node involv case 30/72 41.7 case among case microscop diseas 20.8 case among case macroscop diseas seri result suggest avoid neg slnb tumor patholog examin patient clinic-measur tumor smaller
genom wide express analys techniqu appli breast carcinoma sever result achiev molecular cluster breast carcinoma implement power prognost classif wai predict classif unfortun translat bedsid remain limit due standard difficulti
neodjuv chemotherapi primit us local advanc breast cancer recent indic extend oper lesion sever random trial compar preoper chemotherapi postop surgeri none studi anthracyclin shown benefit term progress free surviv overal surviv rate breast-conserv surgeri seem slightli increas howev nsabp studi margin signific increas local recurr patient convert mastectomi lumpectomi origin plan introduct taxan neoadjuv chemotherapi protocol lead better clinic respons complet histolog respons increas docetaxel us on studi us docetaxel anthracyclin treatment surviv benefit report small studi longer follow updat result nsabp b27 trial need confirm impact taxoter outcom breast cancer integr trastuzumab taxan base chemotherapi alreadi shown high rate histolog complet respons least neoadjuv chemotherapi advantag studi biolog predict factor chemotherapi respons articl will review data standard therapeut agent neoadjuv treatment
twenti year tamoxifen repres gold standard treatment adjuv set breast cancer patient howev tamoxifen activ remain complex agonist effect sometim poor toler certain number patient becom refractori treatment aromatas inhibitor progestatif develop challeng tamoxifen efficaci along improv toler third gener aromatas inhibitor seem provid signific gain efficaci tamoxifen postmenopaus patient hormon receptor posit breast cancer alreadi approv patient metastat diseas review articl rational us patient breast cancer across differ clinic trial result alreadi publish current major role plai adjuv set menopaus hormon receptor-posit breast cancer patient on main issu us third gener long-term side effect especi bone turnov lipid metabol
year high-dose chemotherapi evalu treatment breast cancer numer random clinic trial preliminari result studi shown advantag relaps-free surviv both metastat high-risk breast cancer follow-up short most studi impact overal surviv detect base avail result high-dose chemotherapi propos metastat high-risk breast cancer patient outsid clinic trial convers two random trial demonstr dose-dens schedul chemotherapi g-csf support contain anthracyclin cyclophosphamid paclitaxel improv clinic outcom compar same regimen administ everi week result establish dose-dens schedul chemotherapi contain anthracyclin paclitaxel option adjuv treatment posit lymph node breast cancer patient data suffici conclud neoadjuv metastat set high-dose chemotherapi dose-dens chemotherapi seem increas patholog complet respons rate inflammatori breast cancer howev prospect compar surviv data lack
chemokin receptor involv traffick leucocyt shown recent chemokin receptor cxcr4 ccr7.. express breast cancer cell involv metastasi phenomenon discoveri data gener topic data confirm chemokin receptor involv occurr metastas suggest express regul gene involv carcinogenesi angiogenesi vhl.. inhibitor interest treatment breast cancer paper will review data will discuss perspect open concept
egf receptor slightli express breast cancer suffici impact patient outcom nevertheless determin egfr level repres certain interest order orient target therapi notabl case hormon therapi resist base preclin find preliminari clinic studi result confirm vitro observ possibl encompass hormonotherapi anti-her2 resist futur larg clinic trial necessari redefin strategi treat breast cancer patient
cyclooxygenas cox prostaglandin synthetas enzym plai kei role mammari carcinogenesi sever connect demonstr cox few oncogen v-src v-ha-ra her-2\neu wnt p53 mutat alimentari product pufa transcript factor c-jun c-fo proapoptot protein [bax bcl-x antiapoptot bcl-2 cyp19 aromatas gene nfkappab receptor rankl angiogenesi via vegf txa2 oxid nitric synthetas alphavbeta3 integrin receptor peroxisom gamma prolifer receptor ppargamma ligand pgj2 antitubulin chemotherapi drug correl cox2 express hormon receptor shown epidemiolog studi evid breast cancer risk reduct women take ain lon time alimentari factor like resveratrol insatur fat acid reduc cox2 express anim investig human studi clinic trial plane anti cox2 celecoxib breast cancer prevent adjuv set metastat situat combin exemestan antitubulin drug neoadjuv therapi
purpos aim assess impact comorbid surviv postmenopaus women breast cancer diagnosi period 1995-1997 method level comorbid describ method suggest satariano charlson cox's proport hazard model us explor impact comorbid all-caus mortal result median follow-up time month increas level comorbid associ higher all-caus mortal compar patient with-out comorbid condit hazard ration death 1.2 0.8-1.7 satariano index 2.3 1.5-3.5 satariano index 1.6 2.1 charlson comorbid index respect independ comorbid treatment pattern strong impact surviv level comorbid influenc 3-year surviv postmenopaus women breast cancer conclus long-term follow-up requir apprais find relat treatment strategi
background object kuwait breast cancer most common form cancer among women present studi review clinic featur treatment method treatment result breast cancer patient regist kuwait cancer control center kccc compar featur report arab countri europ north america materi method present studi examin 823 patient breast cancer regist kccc 1993 1998 patient identifi through kuwait cancer registri case follow least five year result eleven male account 1.3 patient.the averag ag on decad younger report western countri similar report egypt gcc countri surgeri appli 90.4 patient breast conserv lumpectomi axillari clearanc perform 19.6 patient mastectomi axillari clearanc adopt 60.8 radiotherapi appli 67.7 patient chemotherapi 60.8 long-term overal surviv diseas-free surviv amount 76+/-6.4 54+/-4.6 respect prognost factor analyz us univari multivari analysi accord multivari analysi nodal statu number involv node histopatholog independ prognost factor compar result achiev both breast conserv mastectomi conclus breast conserv protocol yield result similar mastectomi us extend search biolog prognost indic continu potenti us guid treatment decis
purpos compar prospect trial acut skin reaction late cosmet effect normal fraction versu hypofraction radiotherapi breast conserv surgeri patient method thirti patient 1-2n0m0 breast cancer underw breast conserv surgeri bc includ studi half patient receiv whole breast irradi consist gy/25f/5w+boost 10gy/5f/1w tumor bed group half receiv 42.5gy/16f/22 dai group two group compar earli skin reaction late cosmet result grade accord rtog guidelin result studi show statist signific differ two treatment group regard acut skin reaction cosmet appear howev maximum skin reaction occur week earlier patient group 3rd week compar group 5th week apart breast volum signific correl patient tumor factor incid acut skin reaction group patient patient larg breast volum 1100cc higher rate longer durat maximum skin reaction group week versu week patient small breast volum &lt 1100cc group patient maximum durat 4.5 week differ statist signific median follow-up month differ two group regard cosmet outcom lumpectomi volum lumpectomi/breast volum ratio regardless tumor volum factor significantli affect cosmet appear conclus preliminari result support us shorter fraction schedul 42.5gy/16f/22 dai patient breast conserv surgeri studi still studi late effect larger number patient final evalu regimen
